



OPEN

Glial cells react to closed head injury in a distinct and spatiotemporally orchestrated manner

Ester Nespoli^{1,5}, Marsela Hakani^{1,5}, Tabea Melissa Hein², Stephanie Nadine May², Karin Danzer^{3,4}, Thomas Wirth², Bernd Baumann² & Leda Dimou¹✉

Traumatic brain injury (TBI) is a leading cause of mortality and disability worldwide. Acute neuroinflammation is a prominent reaction after TBI and is mostly initiated by brain-resident glial cells such as microglia, NG2-glia and astrocytes. The magnitude of this reaction paves the way for long-lasting consequences such as chronic neurological pathologies, for which therapeutic options remain limited. The neuroinflammatory response to TBI is mostly studied with craniotomy-based animal models that are very robust but also rather artificial. Here, we aimed to analyze the reaction of glial cells in a highly translational but variable closed head injury (CHI) model and were able to correlate the severity of the trauma to the degree of glial response. Furthermore, we could show that the different glial cell types react in a temporally and spatially orchestrated manner in terms of morphological changes, proliferation, and cell numbers in the first 15 days after the lesion. Interestingly, NG2-glia, the only proliferating cells in the healthy brain parenchyma, divided at a rate that was correlated with the size of the injury. Our findings describe the previously uncharacterized posttraumatic response of the major brain glial cell types in CHI in order to gain a detailed understanding of the course of neuroinflammatory events; such knowledge may open novel avenues for future therapeutic approaches in TBI.

Traumatic brain injury (TBI), with approximately 50–60 million new cases per year, is a leading cause of mortality and disability across all ages worldwide. Low- and middle-income countries, where trauma prevention measures are often insufficient, pay the highest death toll¹. Additionally, in industrialized countries, TBI represents a large burden on the healthcare system because survivors require specialized long-term rehabilitation and are highly susceptible to neurological diseases such as dementia, Alzheimer's disease, and epilepsy, along with depression and other cognitive disturbances^{2–4}.

TBI is caused by an external force that can mechanically deform brain tissue. Its severity can be classified as mild, moderate, or severe according to the patient's consciousness level using the Glasgow Coma Scale, whose score strongly correlates with the outcome of trauma. While mild TBI typically causes only limited acute symptoms and almost no tissue damage, long-term effects have been reported in association with repetitive trauma; however, these long-term effects are still a matter of speculation. In contrast, moderate and especially severe TBI causes widespread tissue damage, skull fractures (hairline cracks), hematoma formation, and, in 30–40% of cases even leads to death^{5,6}.

Therapeutic options for TBI remain limited, and recent clinical trials have failed despite promising preclinical results. One of the major problems in the field remains the narrow translational potential of the most commonly used animal models of TBI, as most of them, including the controlled cortical impact (CCI), stab wound injury (SWI), and fluid percussion injury (FPI) models are based on a craniotomy. On the one hand, these models are highly appreciated for their reproducibility; on the other hand, however, they fail to replicate the complex etiology of human brain trauma^{7–9}.

Another critical obstacle to the discovery of new therapies for TBI is our limited knowledge regarding the kinetics of the cellular processes that initiate and govern the TBI response and, importantly, determine its

¹Molecular and Translational Neuroscience, Department of Neurology, Ulm University, Ulm, Germany. ²Institute of Physiological Chemistry, Ulm University, Ulm, Germany. ³Department of Neurology, Ulm University, Ulm, Germany. ⁴German Center for Neurodegenerative Diseases (DNZE), Ulm, Germany. ⁵These authors contributed equally: Ester Nespoli and Marsela Hakani. ✉email: leda.dimou@uni-ulm.de

outcome. As the brain is an immune-privileged organ, the cellular immune response to TBI is carried out primarily by resident glial cells, such as microglia, astrocytes, and NG2-glia.

Microglia, the resident immune cells of the brain, react rapidly to all forms of brain injury. Within minutes of sensing tissue damage, they modify their morphology and initiate inflammatory processes by releasing cytokines and chemokines, removing cellular debris, and contributing to the remodeling of the extracellular matrix. When the acute trauma reaction is complete, microglial proinflammatory action can persist and cause chronic inflammation as well as long-term neural damage^{10,11}.

Under physiological conditions, NG2-glia, also known as oligodendrocyte progenitor cells, are the only proliferating cells in the adult brain parenchyma, outside the neurogenic niches¹². This unique characteristic allows them to keep their population constant, although they are primarily known for their lifelong ability to differentiate into oligodendrocytes^{13,14}. Even though their regenerative capacity and progenitor status are of clear interest for trauma research, NG2-glia are still understudied compared to other glial cells. Their early polarization, migration, and proliferation around the trauma site, as shown in recent reports, have brought NG2-glia to the spotlight as key contributors to wound closure in the brain^{12,15,16}.

Astrocytes are the most abundant population of glial cells and are responsible for numerous homeostatic functions in the brain. Their acute reaction to various types of brain insults is evidenced by their expression of biomarkers such as glial fibrillary acidic protein (GFAP), which can be upregulated by subsets of astrocytes in the cerebral gray matter even after mild trauma. Upon more severe trauma, GFAP is released into the serum and can be identified there; this principle underlies the use of GFAP as a biomarker after TBI in human. Reactive astrogliosis as the result of moderate or severe trauma is also characterized by the secretion of inflammatory mediators, changes in morphology, and cell proliferation. The most characteristic contribution of astrocytes to trauma resolution is that they coordinate the formation of a glial scar that segregates injured tissue from healthy tissue, thus limiting the spread of damage^{17,18}.

The above-described glial cells can engage in mutual crosstalk and react to an injury to limit tissue damage and re-establish homeostatic functions. To date, studies on the reaction of these cells to injury have mostly focused on a single cell type at a time and predominantly used CCI to model brain trauma. In our study, we addressed the individual and coordinated reaction of microglia, astrocytes, and NG2-glia in a closed head injury (CHI) model, as the strictly timed reaction of each cell type could contribute differently to trauma resolution. Furthermore, we aimed to investigate common trauma parameters that can influence the overall glial cell reaction and could be predictive of the posttraumatic outcome. For this reason, we chose to use a weight-drop CHI mouse model that involves skull exposure but not skull removal and mimics the nature and heterogeneity of human TBI^{19–21}. We observed that the overall glial cell reaction is absent when only skull fracture occurs, while the reaction develops with increased severity of the injury when bleeding also takes place. In the latter case, microglia and NG2-glia are the first cell types to respond to TBI through morphological changes, with the changes beginning one day after TBI, while they reach their maximal proliferation rate only at approximately 3 days after TBI. In contrast, astrocytes react through GFAP upregulation and proliferation later, between 3 and 7 days after trauma. We confirmed the previous observation that scar formation is already visible at 7 days after trauma, and we showed that both the total number of NG2-glia and, more interestingly, the number of actively proliferating NG2-glia correlate directly with the dimensions of the insult, suggesting that NG2-glia are a cell type to watch closely in preclinical trauma research.

Results

Glial cell reaction to TBI is elevated upon increased severity of the injury

To understand the reaction of glial cells to TBI, we used a weight-drop CHI mouse model. This kind of mild injury resulted in the following outcomes regarding the severity degrees: absence of skull fracture or bleeding (mild trauma degree I), only hairline skull fracture (mild trauma degree II), intracerebral bleeding without skull fracture (mild trauma degree III) and finally the more severe paradigm where hairline skull fracture and intracerebral bleeding (mild trauma degree IV) was observed (Fig. 1a,b). The acute cellular reactions associated with the different outcomes of CHI were studied at 3 days after CHI, a timepoint that has previously been associated with the maximal glial reaction after SWI and CCI^{12,22}. In the area directly adjacent to the trauma (yellow area in Supplementary Fig. S1), we immunostained and quantified the glial populations that are mostly involved in TBI repair mechanisms: microglia (Iba1⁺ cells), NG2-glia (NG2⁺ cells), the complete population of astrocytes (S100β⁺ cells) and reactive astrocytes (GFAP⁺ S100β⁺ cells) (Fig. 2; Supplementary Fig. S2). The breakdown of the blood–brain barrier (BBB) in injuries of degree IV was verified with IgG immunohistochemistry (IHC; Supplementary Fig. S3) and was associated with an increased concentration of Iba1⁺ microglia as well as NG2-glia around the trauma site (Fig. 2). While the absolute numbers of the complete population of astrocytes (S100β⁺) was not significantly changed after injury (Supplementary Fig. S2) we could observe an increase in the number of reactive astrocytes as shown by the expression of the GFAP marker (S100β⁺ GFAP⁺ astrocytes; Fig. 2; Supplementary Fig. S2), a protein not expressed in cortical grey matter astrocytes under physiological conditions, but upregulated when astrocytes become reactive as a result of an insult. As cellular accumulation around the injury can be the result of cell proliferation, we administered BrdU to the mice via drinking water, starting one day before the injury and continuing until the timepoint of death; we then quantified BrdU⁺ glial cells. Here, mild trauma of degree III and IV induced a significant increase in glial cell proliferation at 3 days after CHI (Fig. 2f–h), independent of the studied cell type, indicating that increased severity of the CHI exacerbates early glial reactions and especially glial proliferation. The data showing the reaction of astrocytes, specifically the GFAP upregulation and their proliferation, suggest that the increase in the number of GFAP⁺ astrocytes in the mild CHI degree I to III is mainly the result of already existing astrocytes that start expressing GFAP after CHI rather than an increase in the proliferation of reactive astrocytes (Fig. 2b,e,h, Supplementary Fig. S2b). In contrast, in




Figure 1. CHI can lead to different degrees of injury severity. (a) Three days after CHI, the presence of fracture and bleeding (degree IV), only bleeding (degree III), only fracture (degree II), or neither (degree I) could be determined visually on the ipsilateral side of the injury (dotted blue line). (b) Percentages of the different outcomes after CHI.

the injury of degree IV the increase in number of reactive (GFAP⁺) astrocytes results from both, upregulation of GFAP and increased proliferation (Fig. 2e,h, Supplementary Fig. S2b). As we could find a robust reaction of all glial cell types in injuries of severity degree IV, we optimized our setup to reproducibly induce CHI of degree IV (80.23% of all cases), with other outcomes occurring in under 20% of the cases, to better study the reaction of glial cells (Fig. 1b). From now on, we concentrated our study on injuries with a severity degree IV.

The glial cell reaction after CHI is spatially and temporally specific

The acute reaction of glial cells to CHI is necessary to minimize tissue damage, re-establish tissue homeostasis and limit tissue loss. To better understand this complex process, we monitored the reaction of the different glial cell populations 1 day (d), 3 d, 7 d, and 15 d after trauma in mice with higher severity (with skull fracture and bleeding formation; Fig. 3a). The primary trauma site is clearly visible one day after CHI as an area devoid of cellular Iba1- and NG2- staining (black area in Supplementary Fig. S1). At this timepoint, strong, diffuse, non-specific background staining for GFAP could be observed; however, this does not reflect GFAP expression within astrocytes or other cells. Specific astrocytic upregulation of GFAP, which indicates reactive astrocytes, was not visible in the area surrounding the trauma site until 3 days after CHI. The accumulation of microglia and NG2-glia at the border of the trauma site starts between 1 and 3 days after CHI and becomes increasingly clear at later timepoints. Seven days after CHI, a layered arrangement of glial cells can be observed: NG2-glia and Iba1⁺ cells invade the trauma tissue, while GFAP⁺ astrocytes are mainly present at the trauma borders. High expression of Iba1 and NG2, but not GFAP, is also visible alongside the white matter tracts of the corpus callosum as a smear that is directed laterally from the midline. When we studied the breakdown of the blood brain barrier by IgG staining, we could similarly detect increased blood content at the 7 days timepoint laterally to the injury core, although we cannot exclude prior blood infiltration that may have taken place between 3 and 7 days after trauma (Supplementary Fig. S3). Interestingly, this blood infiltration seemed to be completely resolved one week later. At the same timepoint, the core area of the TBI shows intense Iba1- staining, enclosed by NG2⁺ glia and GFAP⁺ astrocytes that have completed the formation of a glial scar. In this study, we stereotactically generated the CHI, making the location of the induced primary injury, which is purely mechanical, reproducible. However, the injury develops differently from animal to animal, leading to a distinct formation of secondary damage, including the destructive and self-propagating biological changes in cells and tissues that lead to their dysfunction or death over hours to weeks after in the initial, primary injury. The distinct and differential development of the secondary trauma also explains the differences in localization of the images in relation to the bregma. However, for our analysis, we only used slices with a by eye visible trauma core. During the initial acute phase after trauma, the injury core, an area lacking glial cells, is clearly visible and widely varies in dimension, while a slight but not significant reduction in the trauma core dimension is progressively observed (Fig. 3b).

The reaction of the different glial populations to CHI is temporally controlled

Having detected that different glial populations display unique dynamics after trauma, we investigated the glial reaction to CHI in more detail. In particular, we followed the cellular changes in Iba1⁺ cells, NG2-glia, and




Figure 2. The response of glial cells to CHI is elevated with increased severity of the injury. (a) Immunohistochemical analysis which shows the injury overview with the use of the nuclear marker DAPI (blue). The yellow line highlights the area that was chosen for analysis regarding cell imaging and quantification. (b) Representative IHC images of higher magnification within the area that was analyzed; BrdU⁺ cells (green) alone or in combination with NG2-glia (red, middle panel), Iba1⁺ cells (microglia, white, left panel), and GFAP⁺ cells (reactive astrocytes, white, right panel) at 3 days after CHI according to the trauma severity. Quantitative analysis of (c) NG2-glia, (d) Iba1⁺ cells, and (e) GFAP⁺ cells in the different degrees of CHI. Quantitative analysis of (f) BrdU⁺ NG2-glia, (g) BrdU⁺ Iba1⁺ cells, and (h) BrdU⁺ GFAP⁺ cells in the different degrees of CHI. Statistical analysis: one-way ANOVA with Tukey’s post hoc test; *p < 0.05, **p < 0.01, ****p < 0.0001. Data are presented as the mean ± SEM.

Iba1 is expressed by brain-resident microglia and infiltrating macrophages, which enter the brain parenchyma through the disturbed blood brain barrier (BBB). Microglia after injury show different morphological states, with ramification, enlargement of processes, and even an amoeboid shape (Fig. 4a and inlays). At this stage, microglia are visually indiscernible from macrophages, and the two cell types work together for optimal removal of cell debris. Iba1⁺ cells showed a sevenfold increase in their abundance around the trauma site between 3 and 15 days after CHI (Fig. 4b). This is paired with intense proliferation, which we were able to track through Ki67 and BrdU staining. We observed that active proliferation (Ki67⁺ signal) of Iba1⁺ cells peaked at 3 days after the trauma and gradually declined but nonetheless persisted in low levels at 15 days after TBI (Fig. 5a). Accordingly, as BrdU labels all cells that have proliferated within the studied time, BrdU⁺ Iba1⁺ cells were more numerous, with their numbers peaking at 7 days after TBI, indicating intense BrdU incorporation into the DNA due to proliferation in the preceding days (Fig. 4e,f, Supplementary Fig. S4). Indeed, more than 80% of all Iba1⁺ cells were proliferating




Figure 4. Glial cell-specific reaction to CHI over time. (a) IHC analysis of Iba1⁺ cells (in gray, left panel), NG2-glia (in red, middle panel), GFAP⁺ astrocytes (in gray, right panel), and proliferating BrdU⁺ cells (in green) shows morphological changes at different time points after CHI. In the images, CHI is located in the upper right corner. Higher magnification images of single cells (yellow dotted line) are shown in insets. (b) Quantification of Iba1⁺ cell-, (c) NG2-glia-, and (d) GFAP⁺ astrocyte-numbers that accumulate around the TBI at different timepoints after CHI. (e) Quantification and identity of BrdU⁺ cells, representing all cells that have proliferated between the timepoint of injury and the timepoint of sacrifice; (f) percentage of the total Iba1⁺ cells, NG2-glia, and GFAP⁺ cells that are also BrdU⁺ at the different time points. Statistical analysis: two-way ANOVA with Tukey's post hoc test for multiple comparisons. *p < 0.05, ****p < 0.0001. Data are presented as the mean ± SEM.




Figure 5. Active proliferation of glial cells changes after injury over time. (a) IHC analysis of Iba1⁺ cells (in gray, left panel), NG2-glia (in red, middle panel), GFAP⁺ astrocytes (in gray, right panel), and actively proliferating Ki67⁺ cells (in green) after CHI. In the images, CHI is located in the upper right corner. Higher magnification images of single cells (yellow dotted line) are shown in insets. (b) Quantification and identity of Ki67⁺ cells, which represent the acute proliferating cells at the timepoint of sacrifice; (c) percentages of all Iba1⁺ cells, NG2-glia, and GFAP⁺ cells that are also Ki67⁺ at the different time points. Correlation of lesion size at 3 (d,g), 7 (e,h) and 15 (f,i) days after trauma with the total number of NG2-glia (d–f) and Ki67⁺ NG2-glia (g–i). A correlation between the size of the lesion and the reaction of NG2-glia could only be observed at 7 days after trauma (e,h). Data are plotted along with the line of fit determined by linear regression analysis. Significance was calculated with R² and p < 0.05.

within the acute phase of the CHI response (Fig. 4e,f), and this reaction was not limited to the ipsilateral side but even extended to the contralateral side (Supplementary Fig. S5).

The reaction of NG2-glia, studied by using the marker NG2, starts early after injury with a clearly visible change in morphology that is temporally restricted to the first day after CHI. At this time point, NG2-glia are hypertrophic but not yet proliferative. As with Iba1⁺ cells, active proliferation for the vast majority of NG2-glia peaked at 3 days after CHI but sharply decreased at later timepoints (Fig. 4a,c,e–f and Fig. 5a–c).

Astrocytes start to become reactive—as shown by GFAP upregulation—at 3 days after CHI and extend their processes to form the astrocytic scar that is visible at 7–15 days after trauma (Fig. 4a,d). These astrocytes show not only morphological changes but also reactivity (GFAP⁺) after CHI. The highest percentage of BrdU⁺ GFAP⁺ cells can be observed at 7 days after CHI, but as the population of actively proliferating astrocytes (Ki67⁺ GFAP⁺ cells) is low at this timepoint (Fig. 5a–c), we conclude that the peak of active proliferation of GFAP⁺ astrocytes takes place between 3 and 7 days after CHI, as has also been described for other injury models¹² (Figs. 4e,f, 5b,c, Supplementary Fig. S4).

The reaction of NG2-glia depends on injury size

After observing that each glial cell type has a spatially and temporally defined reaction, we sought to identify different injury-related parameters that could predict cellular reaction after CHI. We chose to analyze lesion size, as it can be easily measured and compared across different animal injury models. Therefore, we quantified the total numbers of Ki67⁺ cells and concentrated on NG2-glia numbers and their proliferation properties. We excluded day 1 after injury from this analysis because glial cells do not show any major proliferative reaction at this early timepoint (Figs. 4e,f, 5b,c). At three days after injury, when the reaction of NG2-glia and Iba1⁺ cells peaks while the reaction of astrocytes is only starting, we could not observe a correlation between trauma size and the number or proliferation of glial cells. Interestingly, when we analyzed the 7 days timepoint, we could indeed find a correlation of the injury size to the total number of NG2-glia as well as to the number of actively proliferating NG2-glia (Ki67⁺ NG2⁺). Notably, this correlation was resolved at 15 days post injury.

Discussion

TBI is a major cause of mortality and disability worldwide and imposes a great burden on patients, as survivors are likely to develop neurological and cognitive disturbances that require long-term specialized care. Despite intensive research efforts, treatment options for the consequences of neurotrauma remain limited, as preclinical findings often fail to translate to clinical settings^{1,8}. In this study, we performed a comprehensive characterization of the acute glial reaction to neurotrauma in a mouse model of CHI that might better fill the actual gap between preclinical findings and a clinical setting.

While several models of TBI exist, FPI, CCI, and SWI have been the most widely used. These models have been praised for their easy standardization and reproducibility of results, which could correlate to TBI outcomes in patients. However, SWIs account for a minor portion of TBIs in patients²³, and similar to the CCI and FPI models, the SWI model relies on a complex surgical procedure—a craniotomy—which alone can cause intracerebral bleeding, edema formation, inflammation, and worsening of neurological scores²⁴. Furthermore, in the cases of CCI and FPI, the direct impact on the brain causes extensive tissue loss and limits the predictive validity of the models^{7,9}. As a craniotomy itself can lead to glial reaction²² and can provide confounding results, we decided to use a CHI model and optimize it to obtain a rather strong trauma that would induce consistent glial cell reaction.

The weight-drop model is generally used to mimic mild TBI, which is more frequently observed in patients. This procedure is less invasive than open-skull procedures because it requires only sedation and skin incision to expose the skull, which is directly hit by the dropped weight^{20,21}. Interestingly, mice that underwent such an injury do not show any strong abnormalities when monitored by the neurological severity score (NSS) or by their motor behavior²¹. One frequent criticism of the CHI model is its limited reproducibility⁹. Indeed, after CHI, we reported different degrees of severity, and mice were divided into categories regarding the appearance of only brain concussion (degree I), only hairline skull fracture (degree II), only intracerebral bleeding formation (degree III), or a combination of skull fracture and bleeding (degree IV), reflecting the possible TBI outcomes also occurring in patients.

In our study, we focused on understanding the acute cellular reaction of glial cells to neurotrauma to unveil cellular processes that can be targeted or supported for therapeutic purposes after TBI. Surprisingly, we did not observe a substantial difference in the glial cell reaction between the group with only concussion (degree I), hairline skull fracture (degree II), and sham group. Although there are indications that skull fracture alone worsens the neurological severity score in mice²⁵, our data show an acute glial cell reaction only upon increased severity of the injury (degrees III and IV), where intracerebral bleeding is also present. Our findings could be supported by the clinical observation that hematoma formation in patients after TBI was paired with increased oxidative damage, vasogenic edema and cytotoxic edema, as well as heme toxicity²⁶. For these reasons, hematoma in patients is considered as an adverse prognostic factor, leading to progressive neurological deterioration and increased morbidity and mortality after TBI^{27,28}. Intracerebral bleeding could indeed be one but not the only explanation for our findings since its presence in the different injury outcomes was accompanied by a strong glial cell reaction. Indeed, as already known from animal models with intracerebral hemorrhage, the extravasation of blood into the brain provokes brain damage in multiple ways: structural tissue damage is directly induced and cytotoxicity as well as inflammation are introduced by invading peripheral lymphocytes, macrophages, and monocytes as well as by blood-derived components such as immunoglobulins, heme and its degradation products, and damage-associated molecular patterns (DAMPs)²⁹. All these changes after injury could also directly affect the activation of the different resident glial cells in the brain. However, which factors are specifically needed for this activation is still partially unresolved.

Microglia for example, are known to be activated by hemorrhagic DAMPs, e.g., nucleic acids, proteins, lipid mediators, and other molecules released from necrotic and damaged tissue. Within minutes, these cells react through morphological changes, cytokine secretion, and reactive oxygen and nitrogen species production, as shown with CCI, focal cerebral ischemia (FCI), and weight-drop models^{30,31}. In our model, Iba1⁺ cells showed changes only in the stronger severity injury model, where skull break and bleeding was present already at early timepoints after CHI. The observed progressive change from activated to amoeboid shape is supposedly associated with increased phagocytic and inflammatory activity³⁰. When microglia appear amoeboid, they are visually indistinguishable from macrophages, which are also able to express Iba1, albeit at lower levels. For this reason, both cell types are probably included in our quantifications, therefore we refer to them as Iba1⁺ cells. However, other TBI models revealed that the extravasation of macrophages in the brain parenchyma does not occur until approximately one week after TBI and is mainly limited to the core of the insult area³². Therefore, the large increase in Iba1⁺ cell numbers and their accumulation around the TBI observed at 3 days after CHI mostly involves microglia, whereas, at day 7 and 15, both cell types could be involved in the inflammatory processes.

Iba1⁺ cells increase their number through intense proliferation, which we followed through both, Ki67 and BrdU staining. Consistent with studies performed with other TBI models, we identified the most acute proliferative phase of microglia within the first 3 days after trauma^{12,22,33}. As proliferation and therefore Iba1⁺ cell counts gradually decline over the following timepoints, interventions aiming to limit Iba1⁺ cell number increase should be initiated within this timeframe. It is important to mention that microglia can increase their numbers in the area surrounding the trauma by migration even from relatively distant regions³⁴. The mobility of microglia after trauma has been documented in other injury models but could not be addressed within our experiment. Furthermore, we also found proliferating BrdU⁺ microglia on the contralateral side of the brain, supporting the idea that TBI causes global brain inflammation in the long term. This further highlights the importance of understanding how and where immune cells react to an injury, mainly in case one wants to address their reaction pharmacologically for therapeutic purposes.

Previous data have shown, that only invasive injuries such as SWI or cerebral ischemia, rather than noninvasive injuries such as chronic amyloidosis or neuronal cell death, would lead to a reaction of astrocytes and their dedifferentiation^{18,35}. This kind of injuries are generally accompanied by intracerebral bleeding, which leads to tissue disruption and cell death. This suggests that a disturbance of the blood brain barrier is needed for a pronounced glial reaction. At 7 days after TBI, an area of intense Iba1- as well as NG2- staining is visible as a smear along the white matter tract of the corpus callosum, directed away from the midline, suggesting ongoing reactive gliosis in the subregions distant from the injury center. At the same timepoint, IgG staining revealed only moderate blood leakage, possibly suggesting that blood brain barrier restoration and wound closure had already started.

NG2-glia are the least understood among glial cells, and their reaction to TBI was long overlooked until recent findings showed that reactive NG2-glia play a role in brain trauma and wound closure^{16,36}. Also in this study, we observed after CHI a rapid change in the morphology of NG2-glia, followed by increased proliferation peaking at 3 days after trauma and resulting in an increase in the total number of NG2-glia. This increase contributed to their accumulation, which was restricted to the area around the injury core. These data confirmed previous observations derived from other animal models of TBI following craniotomy^{12,15,16,22} and were recently found to facilitate wound closure¹⁶. The accumulation of NG2-glia around the injury core is also known to be supported by short-range migration, and we showed here that the severity as well as the size of the injury can affect the changes in NG2-glia homeostasis and their reaction.

Similar factors were previously observed to alter the NG2-glia reaction following SWI¹⁶. NG2-glia at the injury site might contribute to tissue damage and promote recovery through the release of NG2 protein, a chondroitin sulfate proteoglycan (CSPG4) that physiologically aggregates and forms the extracellular matrix. In fact, a tight and amorphous accumulation of extracellular NG2 protein at the injury border is clearly visible in our immunostaining results. NG2 can also be produced by microglia^{37,38}, while astrocytes release other types of CSPGs^{39,40} to facilitate wound closure. When this deposition is altered, such as in NG2-knockout animals, an exacerbated astrocyte reaction, prolonged blood brain barrier disruption, and slower lesion resolution after SWI were documented⁴¹.

The astrocytic reaction to TBI, termed reactive astrocytosis or astrogliosis, is already shown in different TBI models^{42,43}. Astrogliosis is able to inhibit scar formation after TBI, increase chronic inflammation, and enhance BBB leakiness as well as edema formation, thereby strongly affecting recovery⁴⁴. As most astrocytes in the parenchyma of the cerebral grey matter do not express GFAP under physiological conditions but upregulate it in pathology, GFAP is a well-accepted marker protein for reactive astrocytosis indicating injury or pathology. After TBI in human, GFAP is released in the extracellular milieu and in the blood within minutes, with its amount correlating with trauma severity^{45–47}. As shown in other studies, intracellular upregulation of GFAP in astrocytes of the cerebral grey matter has only started at 3 days after trauma. From this time point onward, astrocytes reorganize their cellular structure, become hypertrophic, prolong their processes (polarization) to reach the borders of the trauma site, and establish the glial scar⁴⁸. At 7 days after trauma, the initial structure of the scar was already visible and at 15 days, scar formation was complete and impenetrable: high IgG and Iba1-staining in the trauma core indicated that brain isolation from the periphery had been restored, while NG2- and GFAP-staining highlighted the borders of the scar. Compared to other glial cells, astrocytic proliferation was delayed and peaked between 3 and 7 days after trauma, similar to what was observed after SWI¹², while after CCI, astrocytic proliferation was already observed at day 3²². Their reaction could be stimulated by factors correlating with the severity of the injury. This is plausible if we consider that astrocytes are fundamental for the physiological maintenance of the BBB and its proper restoration after trauma and are thought to be a valid target for the therapy of hemorrhagic stroke^{44,49,50}.

In summary, this study demonstrated that microglia, astrocytes, and NG2-glia react to TBI, each class with its unique temporal and spatial response that follows a rather standardized procedure even across different animal

models and that can be dramatically altered depending on the trauma severity and the dimension of the injury. An extensive understanding of the course of neuroinflammatory events in this translational brain injury mouse model could open novel avenues for future therapeutic approaches for TBI.

Methods

Animals

Male NMRI mice were housed in a specific-pathogen-free animal facility at Ulm University under standardized conditions (12 h/12 h dark–light cycle; temperature between 20 and 24 °C) and with ad libitum access to food and water. All animal experiments were performed in compliance with the guidelines on the use of animals and humans in neuroscience research as revised and approved by the Regierungspräsidium Tuebingen (Tuebingen, Germany). Ethical approval is obtained from animal ethics committee of the Regierungspräsidium Tuebingen (Tuebingen, Germany).

CHI model

Adult (12–20 weeks old) mice were provided BrdU (bromodeoxyuridine, 1 mg/mL and 1% sucrose) in the drinking water starting 1 day before CHI induction until they were sacrificed. The BrdU water was given in dark flasks and was renewed every 2–3 days to ensure freshness. As drinking water intake and therefore BrdU intake is subject to variability among mice, only mice that showed postmortem positivity to BrdU immunostaining were included in the quantifications. Furthermore, we also compared the cell proliferation of areas far away from the injury site to confirm a rather equal BrdU consumption. On the day of CHI induction, mice were anesthetized with an intraperitoneal (i.p.) injection of ketamine hydrochloride 10%, 100 mg/kg (Pfizer Pharma, Karlsruhe, Germany) and xylazine 2%, 5 mg/kg (Bayer Health Care, Germany) before undergoing experimental CHI with a standardized weight-drop device (for details see^{20,21}). For the procedure, the skull was exposed through a longitudinal incision of the skin, and a focal blunt injury was achieved by dropping a 330 g metal rod with a diameter of 2 mm on the left side of the skull from a height of 2.5 cm onto an impact site at approximately the following stereotaxic coordinates: anteroposterior coordinate = − 1.2 mm and mediolateral coordinate = − 1.5 mm. The falling weight was manually stopped after the impact to avoid rebound injury. Mice were then left to recover in a warm cage, and buprenorphine analgesia (Temgesic; Essex Pharma, Munich, Germany) was administered subcutaneously (0.03 mg/kg body weight) immediately after trauma and again at 6 h and 24 h after trauma. For the whole duration of the experiment, mice were closely monitored, and only animals with no visible signs of pain were included in the study. Sham animals underwent the same experimental procedure except for the weight-drop injury.

Postmortem sample preparation

For the analysis of the glial reaction after different severity degrees of the injury, mice were sacrificed 3 days after CHI or sham procedure (sham: n = 5, degree I: n = 4; degree II: n = 3, degree III: n = 3; degree IV: n = 7; n reflects single animals). For the analysis of glial cell reaction, mice were sacrificed 1 day, 3 days, 7 days, and 15 days following CHI (5–7 mice per group). In the latter case, only mice that showed an injury of severity degree IV were included in the study, along with sham mice (sham: n = 5–6 per timepoint (1, 3, 7 and 15 days), CHI: n = 5–7 per timepoint (1, 3, 7 and 15 days); n reflects single animals). For postmortem analysis, animals were anesthetized with an i.p. injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) diluted in a 0.9% NaCl solution. For tissue fixation, transcardial perfusion was performed, first with 25 mL of ice-cold PBS to flush out the blood, followed by 50 mL of ice-cold 4% PFA in PBS. Brains were extracted and further postfixed in 4% PFA for 2 h, transferred to a solution of 30% saccharose in PBS at 4 °C overnight for cryoprotection, and stored at 4 °C until use.

Histology and immunofluorescence staining

For immunohistochemistry, the brain samples were cryosectioned into 20 µm-thick slices, and each slide contained 3–4 sequential brain slices. Different cellular markers were stained on each slice. Only slides that visibly included the core of the trauma were selected and included in the study. Brain slices were permeabilized and blocked in a solution of 5% BSA in PBS with 0.5% Triton and incubated with primary antibodies in blocking solution overnight at 4 °C. After washing with PBS, slices were incubated with secondary antibodies in blocking solution for 2 h at room temperature. For nuclear antibodies, heat-mediated antigen retrieval was needed and was performed with sodium citrate (10 mM, pH 6.0, 0.05% Tween 20) before incubation with the primary antibody. When both nuclear and nonnuclear antibodies were used at the same time, only nonnuclear antibodies were incubated at first and were then fixed with 4% PFA before antigen retrieval. After antigen retrieval, the slices were incubated with both nuclear and nonnuclear antibodies. The following primary antibodies were used: rabbit α-NG2 (1:250, Merck #AB5320), rat α-Ki67 (1:250, Thermo Fisher Scientific #14-5698-82), rat α-BrdU (1:250, Abcam #ab6326), guinea pig α-Iba1 (1:500, Synaptic Systems #234004), mouse α-GFAP (1:500, Sigma-Aldrich #G3893) and mouse α-S100β (1:250, Sigma-Aldrich #S2532). The following secondary antibodies were used for immunodetection of the aforementioned primary antibodies: α-rat Alexa Fluor[®] 488 (1:500, Thermo Fisher #A21208), α-mouse IgG Alexa Fluor[®] 647 (1:500, Dianova #115-606-072), α-guinea pig IgG Alexa Fluor[®] 647 (1:500, Thermo Fisher #A21450), and α-rabbit Cy³ 3 (1:500, Dianova #711-165-152). Finally, slices were washed with PBS, incubated with DAPI at a 1:1000 dilution for nuclear counterstaining for 10 min, and then mounted on a slide with Aqua-Poly/Mount. In glial proliferation studies, the marker NG2 was always present to consistently determine the area of imaging across different slices and samples and used together with a proliferation marker (Ki67 or BrdU) and with either Iba1 or GFAP. This facilitated the recognition of the same area to use for image acquisition.

Image acquisition and cellular quantification analysis

For image acquisition, only slides containing the CHI core were considered. Overview images of the trauma area were acquired with a Keyence BZ-9000 BioRevo microscope (Keyence, Neu-Isenburg, Germany) with filters for DAPI, FITC/Alexa Fluor 488, Texas Red/Alexa Fluor 568/594 and Cy5 at 10× and 20× magnification. These images were then used for the analysis of the trauma dimension, which was manually done through Fiji (based on ImageJ 1.48i) software, considering a total of 3 slices per animal and 7–10 mice per timepoint. For cellular quantification around the area of trauma, the perilesional area adjacent to the CHI was specified (yellow area in Supplementary Fig. S1), and image acquisition was performed with a Leica SPE confocal microscope at 40× magnification and analyzed through Fiji (ImageJ). For every immunostaining, 4–12 images were quantified for each mouse, depending on the availability of the slides containing the injury core. Only cells that were positive for the selected markers and contained visible DAPI signal were taken into consideration in the analysis. The Iba1 antibody was used to identify microglia and macrophages, and the GFAP antibody was used to identify reactive astrocytes. For NG2-glia quantification, in addition to NG2 staining, the presence of a ramified cellular morphology and a localization not adjacent to any blood vessel were applied as criteria to avoid confusion with NG2⁺ pericytes. All data were analyzed in a blinded manner. All quantitative data are reported as the mean ± SEM. No statistical method was used to determine the sample size; instead, it was purely based on previous studies in the field. The significance of our quantification was tested by one-way or two-way ANOVA with Tukey's post hoc test for multiple comparisons. Data were considered significant at p value < 0.05 = *, p value < 0.01 = **, p value < 0.001 = *** and p value < 0.0001 = ****. All statistical analyses were performed with GraphPad Prism 9.

Ethical approval

All animal experiments were performed in accordance with the guidelines on the use of animals and humans in neuroscience research as revised and approved by the Regierungspräsidium Tuebingen. Ethical approval is obtained from animal ethics committee of the Regierungspräsidium Tuebingen (Tuebingen, Germany).

ARRIVE guidelines

The study is reported following the recommendations of the ARRIVE guidelines.

Data availability

The raw data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 2 February 2023; Accepted: 17 January 2024

Published online: 30 January 2024

References

1. Maas, A. I. R. *et al.* Traumatic brain injury: Integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol.* **16**, 987–1048 (2017).
2. Lew, H. L. *et al.* Persistent problems after traumatic brain injury: The need for long-term follow-up and coordinated care. *J. Rehabil. Res. Dev.* **43**, vii (2006).
3. Plassman, B. L. *et al.* Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. *Neurology* **55**, 1158–1166 (2000).
4. Quaglio, G., Gallucci, M., Brand, H., Dawood, A. & Cobello, F. Traumatic brain injury: A priority for public health policy. *Lancet Neurol.* **16**, 951–952 (2017).
5. Rosenfeld, J. V. *et al.* Early management of severe traumatic brain injury. *Lancet Lond. Engl.* **380**, 1088–1098 (2012).
6. Teasdale, G. *et al.* The Glasgow Coma Scale at 40 years: Standing the test of time. *Lancet Neurol.* **13**, 844–854 (2014).
7. Kabadı, S. V. & Faden, A. I. Neuroprotective strategies for traumatic brain injury: Improving clinical translation. *Int. J. Mol. Sci.* **15**, 1216–1236 (2014).
8. DeWitt, D. S. *et al.* Pre-clinical testing of therapies for traumatic brain injury. *J. Neurotrauma* **35**, 2737–2754 (2018).
9. Ma, X., Aravind, A., Pfister, B. J., Chandra, N. & Haorah, J. Animal models of traumatic brain injury and assessment of injury severity. *Mol. Neurobiol.* **56**, 5332–5345 (2019).
10. Karve, I. P., Taylor, J. M. & Crack, P. J. The contribution of astrocytes and microglia to traumatic brain injury. *Br. J. Pharmacol.* **173**, 692–702 (2016).
11. Loane, D. J. & Kumar, A. Microglia in the TBI brain: The good, the bad, and the dysregulated. *Exp. Neurol.* **275**, 316–327 (2016).
12. Simon, C., Götz, M. & Dimou, L. Progenitors in the adult cerebral cortex: Cell cycle properties and regulation by physiological stimuli and injury. *Glia* **59**, 869–881 (2011).
13. Dimou, L., Simon, C., Kirchhoff, F., Takebayashi, H. & Götz, M. Progeny of Olig2-expressing progenitors in the gray and white matter of the adult mouse cerebral cortex. *J. Neurosci.* **28**, 10434–10442 (2008).
14. Bernhardt, J. E. & Dimou, L. NG2-glia, more than progenitor cells. In *Glial Cells in Health and Disease of the CNS* 27–45 (Springer, 2016). https://doi.org/10.1007/978-3-319-40764-7_2.
15. Wellman, S. M. & Kozai, T. D. Y. In vivo spatiotemporal dynamics of NG2 glia activity caused by neural electrode implantation. *Biomaterials* **164**, 121–133 (2018).
16. von Streitberg, A. *et al.* NG2-Glia transiently overcome their homeostatic network and contribute to wound closure after brain injury. *Front. Cell Dev. Biol.* **9**, 662056 (2021).
17. Sofroniew, M. V. & Vinters, H. V. Astrocytes: Biology and pathology. *Acta Neuropathol. (Berl.)* **119**, 7–35 (2010).
18. Escartin, C. *et al.* Reactive astrocyte nomenclature, definitions, and future directions. *Nat. Neurosci.* **24**, 312–325 (2021).
19. Chen, S., Pickard, J. D. & Harris, N. G. Time course of cellular pathology after controlled cortical impact injury. *Exp. Neurol.* **182**, 87–102 (2003).
20. Flierl, M. A. *et al.* Mouse closed head injury model induced by a weight-drop device. *Nat. Protoc.* **4**, 1328–1337 (2009).
21. Mettang, M. *et al.* IKK2/NF-κB signaling protects neurons after traumatic brain injury. *FASEB J.* **32**, 1916–1932 (2018).
22. Susarla, B. T. S., Villapol, S., Yi, J.-H., Geller, H. M. & Symes, A. J. Temporal patterns of cortical proliferation of glial cell populations after traumatic brain injury in mice. *ASN Neuro* **6**, 25 (2014).

23. Yarandi, K. K. *et al.* Stab wounds to the head; case series, review of literature, and proposed management algorithm. *Asian J. Neurosurg.* **13**, 754–759 (2018).
24. Cole, J. T. *et al.* Craniotomy: True sham for traumatic brain injury, or a sham of a sham?. *J. Neurotrauma* **28**, 359–369 (2011).
25. Zvejniece, L. *et al.* Skull fractures induce neuroinflammation and worsen outcomes after closed head injury in mice. *J. Neurotrauma* **37**, 295–304 (2020).
26. Lok, J. *et al.* Intracranial hemorrhage—mechanisms of secondary brain injury. *Acta Neurochir. Suppl.* **111**, 63–69 (2011).
27. Armin, S. S., Colohan, A. R. T. & Zhang, J. H. Traumatic subarachnoid hemorrhage: Our current understanding and its evolution over the past half century. *Neurol. Res.* **28**, 445–452 (2006).
28. Griswold, D. P., Fernandez, L. & Rubiano, A. M. Traumatic subarachnoid hemorrhage: A scoping review. *J. Neurotrauma* **39**, 35–48 (2022).
29. Aronowski, J. & Zhao, X. Molecular pathophysiology of cerebral hemorrhage: Secondary brain injury. *Stroke J. Cereb. Circ.* **42**, 1781–1786 (2011).
30. Donat, C. K., Scott, G., Gentleman, S. M. & Sastre, M. Microglial activation in traumatic brain injury. *Front. Aging Neurosci.* **9**, 25 (2017).
31. Lier, J., Ondruschka, B., Bechmann, I. & Drefßler, J. Fast microglial activation after severe traumatic brain injuries. *Int. J. Legal Med.* **134**, 2187–2193 (2020).
32. Alam, A. *et al.* Cellular infiltration in traumatic brain injury. *J. Neuroinflamm.* **17**, 328 (2020).
33. Itoh, T. *et al.* Exercise increases neural stem cell proliferation surrounding the area of damage following rat traumatic brain injury. *J. Neural Transm.* **118**, 193–202 (2011).
34. Kim, W. R. *et al.* Regional difference of reactive astrogliosis following traumatic brain injury revealed by hGFAP-GFP transgenic mice. *Neurosci. Lett.* **513**, 155–159 (2012).
35. Sirko, S. *et al.* Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. *Cell Stem Cell* **12**, 426–439 (2013).
36. Viganò, F. *et al.* GPR17 expressing NG2-Glia: Oligodendrocyte progenitors serving as a reserve pool after injury. *Glia* **64**, 287–299 (2016).
37. Zhu, L. *et al.* NG2 expression in microglial cells affects the expression of neurotrophic and proinflammatory factors by regulating FAK phosphorylation. *Sci. Rep.* **6**, 27983 (2016).
38. Huang, W., Bai, X., Meyer, E. & Scheller, A. Acute brain injuries trigger microglia as an additional source of the proteoglycan NG2. *Acta Neuropathol. Commun.* **8**, 146 (2020).
39. Burda, J. E., Bernstein, A. M. & Sofroniew, M. V. Astrocyte roles in traumatic brain injury. *Exp. Neurol.* **275**, 305–315 (2016).
40. Haas, C. A., Rauch, U., Thon, N., Merten, T. & Deller, T. Entorhinal cortex lesion in adult rats induces the expression of the neuronal chondroitin sulfate proteoglycan neurocan in reactive astrocytes. *J. Neurosci.* **19**, 9953–9963 (1999).
41. Huang, C. *et al.* Lack of NG2 exacerbates neurological outcome and modulates glial responses after traumatic brain injury. *Glia* **64**, 507–523 (2016).
42. Burda, J. E. *et al.* Divergent transcriptional regulation of astrocyte reactivity across disorders. *Nature* **606**, 557–564 (2022).
43. Yuan, M. & Wu, H. Astrocytes in the traumatic brain injury: The good and the bad. *Exp. Neurol.* **348**, 113943 (2022).
44. Sofroniew, M. V. Reactive astrocytes in neural repair and protection. *Neuroscientist* **11**, 400–407 (2005).
45. Lumpkins, K. M. *et al.* Glial fibrillary acidic protein is highly correlated with brain injury. *J. Trauma* **65**, 778–782 (2008) (**discussion 782–784**).
46. Lei, J. *et al.* Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: A prospective cohort study. *Crit. Care* **19**, 362 (2015).
47. Abdelhak, A. *et al.* Blood GFAP as an emerging biomarker in brain and spinal cord disorders. *Nat. Rev. Neurol.* **18**, 158–172 (2022).
48. Bardehle, S. *et al.* Live imaging of astrocyte responses to acute injury reveals selective juxtavascular proliferation. *Nat. Neurosci.* **16**, 580–586 (2013).
49. Bush, T. G. *et al.* Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. *Neuron* **23**, 297–308 (1999).
50. Scimemi, A. Astrocytes and the warning signs of intracerebral hemorrhagic stroke. *Neural Plast.* **2018**, 7301623 (2018).

Acknowledgements

The authors are thankful to Petra Wehrich, Diana Giesler and Simon Köpff for the excellent technical support. We also thank the animal caretakers at Ulm University. Furthermore, we are grateful to Katrin Volbracht, Antonio Miralles Infante, Aladdin Skaf, Lea Jäger, Paula Klassen and Konstantinos Tsesselis for their helpful feedback. This project was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-Collaborative Research Center (CRC) SFB 1149 (Project-ID 251293561).

Author contributions

L.D. conceived the project, designed and supervised the experiments, discussed the results, coordinated and directed the project. E.N. and L.D. designed the study. B.B. and T.W. provided the animals and the TBI equipment. K.D. provided advice and commented on the manuscript. E.N., M.H., T.M.H., and S.N.M. performed the in vivo injury experiments. E.N. and M.H. performed the postmortem analyses, brain imaging, cellular quantifications, and statistical analyses. E.N., M.H. and L.D. wrote the manuscript and all authors participated in correcting the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-024-52337-4>.

Correspondence and requests for materials should be addressed to L.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024